Promising patient data surrounding the medication Retatrutide , specifically the high-dose formulation ZPHC ZPHC, reveal a considerable effect on physique reduction and related metabolic illnesses . Experts anticipate that this dual agonist , affecting both GLP-1 and GIP pathways , could offer a noteworthy advance in the management of overweight a